XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
   Tigecycline
   Sirolimus
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38
Randomised Control Trial
MOTIV (Moxifloxacin Treatment Intravenous) study

Antibiotics Channel
subscribe to Antibiotics newsletter

Latest Research : Pharmacology : Antibiotics

   DISCUSS   |   EMAIL   |   PRINT
Avelox (Moxifloxacin) is as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
Apr 9, 2006, 12:44, Reviewed by: Dr. Vineet Gupta

"CAP can critically affect older patients who may be struggling with existing conditions such as heart disease and diabetes. These results provide additional evidence that AVELOX is a safe and effective treatment for patients with CAP."

 
AVELOX (moxifloxacin HCl) monotherapy at 400 mg once daily is as effective as the high-dose combination of levofloxacin (500 mg twice daily) plus ceftriaxone (2 g once daily) in treating patients with severe community-acquired pneumonia (CAP) requiring hospitalization, according to results of a new clinical study presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Nice, France.

Known as the MOTIV (Moxifloxacin Treatment Intravenous) study, the head-to-head comparison of once-daily AVELOX monotherapy to a combination of high-dose levofloxacin plus high-dose ceftriaxone showed no significant difference in clinical cure rates (4-14 days after the last dose), the primary efficacy endpoint for the two per protocol treatment groups (86.9 percent vs. 89.9 percent, respectively), including CAP patients with the most severe pneumonia.

The per protocol population consisted of 569 patients. A total of 748 patients were enrolled in the study, of which 738 patients were randomized. Both treatments were well tolerated in the study, with similar adverse event profiles.

"The results of the MOTIV study are important because community-acquired pneumonia is a particular concern for people with chronic illnesses or impaired immune systems, and is a common cause of hospitalization worldwide," said Antoni Torres, M.D., professor of pulmonology at the University of Barcelona in Spain.

"CAP can critically affect older patients who may be struggling with existing conditions such as heart disease and diabetes," he added. "These results provide additional evidence that AVELOX is a safe and effective treatment for patients with CAP."

CAP affects approximately 5.6 million adults in the United States each year, with elderly patients (age 65 and above) 60 percent more likely than the general population to develop the infection.
 

- Schering-Plough Corporation
 

Schering-Plough

 
Subscribe to Antibiotics Newsletter
E-mail Address:

 

AVELOX, a broad-spectrum fluoroquinolone antibiotic, has been shown to be safe and effective as monotherapy in treating patients with CAP and is approved for this indication

Related Antibiotics News

Two-component lantibiotic with therapeutic potential discovered
Antibiotic inhibits cancer gene activity
Rapamycin shown to inhibit angiogenesis
Tigecycline, world’s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
FDA Warns of Liver Failure With Telithromycin
What is the optimal duration of antibiotic therapy?
Should children with suspected meningitis be given antibiotics before transfer to hospital?
Production Practices Effect Antimicrobial Resistance in Poultry
Aspirin Protects Against Aminoglycoside Induced Hearing Loss
Avelox (Moxifloxacin) is as effective as Levofloxacin combination therapy for severe community-acquired pneumonia


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us